Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

High-throughput Screening (HTS) Market to Grow from USD 27.66 Billion in 2026 to USD 45.90 Billion by 2031, at a CAGR of 10.7% – MarketsandMarkets™

globenewswire.com
TMO Thermo Fisher Scientific leads the HTS market with a broad portfolio, indicating strong positioning and growth potential in this expanding sector. A Agilent Technologies has strengthened its position in the HTS market with its microplate readers, imaging systems, and automation platforms, suggesting positive market performance. MRK Merck KGaA is a major supplier of assay kits and reagents for HTS, indicating a significant and likely growing role in the expanding market. DHR Danaher Corporation is mentioned as a leading participant investing in automation and HTS services, suggesting a positive outlook due to market growth. BIO Bio-Rad Laboratories is noted as a key participant investing in automation and HTS services, indicating positive growth prospects in the expanding HTS market. CRC Charles River Laboratories is mentioned as a key participant investing in outsourced HTS services, suggesting positive growth due to the expanding market. EFSC Eurofins Scientific is listed as a key participant investing in outsourced HTS services, indicating positive growth prospects within the expanding HTS market. CC Corning Incorporated is listed as a key participant investing in automation and HTS services, suggesting positive growth due to the expanding HTS market.

High-throughput Screening (HTS) Market to Grow from USD 27.66 Billion in 2026 to USD 45.90 Billion by 2031, at a CAGR of 10.7% – MarketsandMarkets™ Delray Beach, FL, July 20, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global high-throughput screening (HTS) market will grow from USD 27.66 billion in 2026 to USD 45.90 billion by 2031, at a CAGR of 10.7% during the forecast period. Market growth is driven by increasing pharmaceutical and biotechnology R&D investments, growing adoption of automated drug discovery platforms, rising government funding and venture capital investments, and technological advancements in high-content screening, cell-based assays, artificial intelligence-enabled analytics, and laboratory automation. The expanding use of outsourced drug discovery models, 3D cell cultures, organoids, and advanced screening platforms is further accelerating market growth.

Get PDF Brochure - Market Data & Segmentation: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950

Key Market Highlights

Why This Market Matters

High-throughput screening has become a cornerstone of modern drug discovery by enabling researchers to rapidly evaluate thousands to millions of compounds, genes, and biological targets. As pharmaceutical and biotechnology companies accelerate drug development pipelines, HTS technologies are helping reduce discovery timelines, improve hit identification, and enhance target validation. Advances in automation, high-content imaging, AI-powered data analysis, phenotypic screening, and biologically relevant models such as 3D cell cultures and organoids are significantly improving screening efficiency and decision-making across research workflows.

Market Overview

The HTS market continues to evolve through increasing automation, integration of artificial intelligence, and adoption of biologically relevant screening models. Pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic research institutes are investing in automated liquid handling systems, microplate technologies, imaging platforms, assay kits, and laboratory informatics to improve screening throughput and reproducibility. Growing outsourcing of early-stage drug discovery and expanding collaborations between pharmaceutical companies, CROs, and research institutions are further strengthening market expansion.

Analyst Perspective

The HTS industry is shifting toward intelligent, highly automated drug discovery ecosystems that integrate robotics, high-content imaging, AI-enabled analytics, and cloud-based laboratory informatics. Organizations capable of combining advanced screening technologies with scalable automation, sophisticated data analysis, and biologically relevant assay platforms will be well positioned to address the growing complexity of modern drug discovery. Continued investment in precision medicine, biologics, and next-generation therapeutic development is expected to create substantial long-term opportunities for HTS technology providers.

Speak to Our Analyst - Get Custom Insights: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=134981950

Segment Analysis

By offering, the products segment accounted for the largest share of the HTS market in 2025. Recurring demand for assay kits, reagents, consumables, microplates, compound libraries, automation platforms, instruments, and software throughout screening workflows continues to generate the largest revenue contribution across the market.

By product type, reagents, kits & consumables held the largest market share due to their extensive use in biochemical assays, cell-based assays, sample preparation, compound screening, detection reactions, and secondary validation. Their recurring usage across multiple screening workflows drives sustained market demand.

By technology, cell-based screening dominated the HTS market because it provides biologically relevant insights by evaluating compound activity in living cells. Growing adoption of phenotypic screening, high-content imaging, organoids, and 3D cell culture models is further supporting segment growth.

By service type, primary screening services accounted for the largest share of the HTS services market. Pharmaceutical and biotechnology companies increasingly outsource large-scale compound, gene, and cell library screening to specialized service providers with advanced automation infrastructure and assay expertise.

By application, drug discovery & development represented the largest market segment owing to widespread use of HTS for hit identification, target validation, lead optimization, and early-stage therapeutic discovery across small molecules, biologics, and precision medicine programs.

Regional Analysis

Asia Pacific is projected to register the highest CAGR in the high-throughput screening market during the forecast period. Market growth is supported by expanding pharmaceutical and biotechnology research activities, increasing CRO presence, rising government investments in life science research, and growing adoption of automated screening platforms across China, India, Japan, South Korea, and other emerging markets. Cost-efficient research infrastructure, expanding biotechnology ecosystems, and increasing collaborations between pharmaceutical companies, CROs, academic institutions, and government research organizations continue to strengthen regional HTS capabilities.

Key Industry Trends

Competitive Landscape

The high-throughput screening market is highly competitive, with global life science companies strengthening their portfolios through product innovation, acquisitions, partnerships, and laboratory automation technologies. Thermo Fisher Scientific leads the market with a broad portfolio spanning reagents, consumables, instruments, software, imaging systems, liquid handling platforms, and laboratory services. Agilent Technologies has strengthened its position through BioTek microplate readers, cell imaging systems, automation platforms, and workflow software. Merck KGaA remains a major supplier of assay kits, compound libraries, biological reagents, and screening consumables. Other leading participants, including Danaher Corporation, Revvity, Tecan Group, Bio-Rad Laboratories, Charles River Laboratories, Eurofins Scientific, Sartorius AG, Hamilton Company, and Corning Incorporated, continue investing in automation, high-content screening, assay development, and outsourced HTS services to expand their global market presence. The top players collectively account for approximately 38% of the global HTS market.

Related Reports

Lab Automation Market

Biochips Market